

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **November, 2018**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: November 27, 2018

By: /s/ Pierre Labbé  
Name: Pierre Labbé  
Title: Chief Financial Officer

---

Form 6-K Exhibit Index

**Exhibit  
Number**

**Document Description**

[99.1](#)

[News Release dated November 27, 2018. Presenting Respiratory Syncytial Virus \(RSV\) Research at RespiDART 2018](#)

---

**FOR IMMEDIATE RELEASE****IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018**

**Dartmouth, Nova Scotia; November 26, 2018** –IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV program at “[RespiDART: Frontiers in Drug Development against Respiratory Viruses.](#)” The conference will take place in Miami, Florida, from November 29 - 30, 2018 at the Marriott Miami Biscayne Bay.

Members of IMV’s leadership will share data via an oral presentation as well as a poster session. Details are as follows:

<b>Name:</b>	‘Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV Small Hydrophobic protein’
<b>Presenter:</b>	Genevieve Weir, PhD, Director of Research, IMV Inc.
<b>Oral Presentation:</b>	Oral Abstracts, Session 3
<b>Date:</b>	Friday, November 30, 2018
<b>Time:</b>	12:00 – 12:10 p.m. ET
<b>Location:</b>	Grand Ballroom
<b>Poster Presentation:</b>	Abstract #105
<b>Date/Time:</b>	November 29 at 3:00 p.m. to November 30 at 6:00 p.m. ET
<b>Location:</b>	Salon F & G

**About RESPIDART**

[RespiDART](#) is a new addition to the DART series of healthcare conferences and is focused on drug development challenges and advances for respiratory virus threats to human health. These viruses include long-standing threats such as RSV and influenza, as well as recent outbreaks of MERS-coV, parainfluenza virus, and metapneumovirus. This meeting will focus on advances in therapeutics, vaccinology, virus/host interactions and enzymology, and new study models in development. By bringing together world leaders and key opinion holders, RespiDART 2018 aims to address the latest challenges in vaccine and drug development against respiratory viruses.

## **About IMV**

IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at [www.imv-inc.com](http://www.imv-inc.com).

###

## **Contacts for IMV:**

### **MEDIA**

**Mike Beyer, Sam Brown Inc.**

T: (312) 961-2502 E: [mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com)

### **INVESTOR RELATIONS**

**Pierre Labbé, Chief Financial Officer**

T: (902) 492-1819 E: [info@imvaccine.com](mailto:info@imvaccine.com)

**Patti Bank, Managing Director, Westwicke Partners**

O: (415) 513-1284

T: (415) 515-4572 E: [patti.bank@westwicke.com](mailto:patti.bank@westwicke.com)

---